What are my options for losing weight? Where GLP-1 medicines fit
Food and activity, NHS programmes, orlistat, GLP-1 medicines, balloons and surgery, side by side, with NHS criteria and costs.
There are five main routes:
- Lifestyle changesFood, activity and support. The base for all the others.
- An older weight-loss pillOrlistat, on prescription or at a lower dose from a pharmacy. It helps a little.
- GLP-1 medicinesSuch as semaglutide (Wegovy) and tirzepatide (Mounjaro)
- Endoscopic proceduresDone through the mouth, without cutting the skin
- Weight-loss surgeryThe largest, longest-lasting loss, but a major operation
They differ a lot in weight lost, risk and cost. Medicines, procedures and surgery are added to lifestyle changes, not used instead of them. Procedures and surgery are only for much higher BMIs. Talk to your GP before starting, stopping or changing any treatment. See which are for you
Key facts
- Lifestyle programmes
- About 9% of body weight lost after 1 year in a large trial, 6% after 10 years1
- GLP-1 medicines
- About 15–21% lost in trials of people without diabetes. Weight returns after stopping.4,5,6
- Surgery
- The largest and longest-lasting loss: about 25% of body weight 10 years after a gastric bypass, with operation risks7,8
- NICE's view
- Every weight-loss medicine should go alongside a reduced-calorie diet and more activity9
On this page
- Which options are for you?
- How do the options compare?
- Can food and activity changes alone help?
- What about pills, and other medicines that lower weight a little?
- Where do GLP-1 medicines fit?
- Who is weight-loss surgery for in the UK?
- What are gastric balloons and endoscopic sleeves?
- How does the NHS build up care?
- Questions people ask
Which options are for you?
It depends mostly on your BMI and your health. Lifestyle changes are for everyone. Medicines come in at a lower BMI. Procedures and surgery are for much higher weights.
So if your BMI is in the high 20s, the choice is usually between lifestyle changes alone and lifestyle changes plus a medicine. At 170 cm (5 ft 7 in), a BMI of 27 is about 78 kg (12 st 4 lb). NHS surgery usually starts around a BMI of 35 to 40, about 101 to 116 kg (15 st 13 lb to 18 st 4 lb) at the same height.10,9
The NHS and a medicine's licence use different numbers. The licence says who a medicine can be prescribed for. A private prescriber can use it from a BMI of 30, or 27 with a condition such as high blood pressure, and the licence doesn't lower that for any ethnic group.10 NHS criteria are stricter: NICE recommends Mounjaro from a BMI of 35 with at least one weight-related condition, and the NHS in England is offering it to the highest-need groups first.9,13 See Mounjaro on the NHS.
These are points where you and a doctor can start a conversation, not rules that you must or must not have something. Guidelines also look at your health, not just your weight.9,8
How do the options compare?
In trials, surgery led to the most weight loss. GLP-1 medicines came next, but only while people kept taking them. Lifestyle programmes and pills led to less.
The numbers below come from different trials, with different people. So treat them as rough guides. They are not a direct comparison. "Weight lost" is the average share of starting body weight.
- Dummy injection (for comparison)2–3 kg4,5
- Orlistat (pill)~3 kg more than a dummy pill2
- Lifestyle programme~8 kg1
- Gastric balloon~9 kg11
- Endoscopic sleeve (ESG)~12 kg12
- GLP-1 medicine~13–19 kg4,5
- Gastric bypass surgery~23–29 kg7
Rough guide only: different trials, different people and different lengths of time. Details for each option are below.
Each option in detail. Weight lost is the average share of starting weight.
Lifestyle programme
OngoingA structured plan: a calorie target, regular activity, and regular sessions with a dietitian or coach. More ↓
Orlistat (pill)
OngoingA capsule taken with meals, up to 3 times a day, that stops some of the fat you eat from being absorbed. More ↓
Over 4 years2
GLP-1 medicine
OngoingA weekly injection or daily tablet that makes you less hungry. Explained in Guide 2. More ↓
Gastric balloon
One-off, temporaryA soft balloon is put into your stomach through the mouth, so there's less room for food. It's taken out after about 6 months. More ↓
At 6 months, about 8% at 1 year11
Endoscopic sleeve (ESG)
One-offStitches are put inside your stomach through the mouth to make it smaller. No cuts in the skin. More ↓
At 1 year12
Weight-loss (bariatric) surgery
One-off, lifelong follow-upAn operation that makes your stomach much smaller. Some types, like gastric bypass, also reroute the gut so food skips part of it. More ↓
Gastric bypass: 32% at its peak (1–2 years), 25% at 10 years7
We show only official prices: NHS prescription charges and the maker's list price published by NICE. Private clinics and pharmacies set their own prices, and we don't list or compare them. GLP-1 and orlistat costs repeat every month.
In the medicine trials, the dummy-injection groups lost 2.4% and 3.1%, or about 2–3 kg.4,5 These are averages, and results vary from person to person. In those trials, about 14 in 100 people on semaglutide and 9 in 100 on tirzepatide lost less than 5% of their weight.4,5
Can food and activity changes alone help?
Yes, for many people. Structured programmes helped people lose around 6–9% of their weight, and cut their risk of diabetes.
One large trial, Look AHEAD, followed 5,145 adults with type 2 diabetes.1 The programme set a calorie target and about 3 hours of activity a week, with frequent group and one-to-one sessions.1 People lost 8.6% of their weight in the first year, against 0.7% with usual care.1 After about 10 years, they were still 6.0% lighter, against 3.5%.1
In the US Diabetes Prevention Program, 3,234 people with high blood sugar (prediabetes) took part.26 The lifestyle group lost 5.6 kg (about 12 lb) on average over about 3 years, against 0.1 kg on a dummy pill.26 Their rate of new diabetes was 58% lower: 4.8 cases per 100 people a year, against 11.0.26
Food: how much to cut
To lose weight, NICE says you need to take in less energy than you use, whether by eating less fat, fewer carbohydrates or another method.25 US guidelines put a number on it: about 500–750 calories a day less than your body uses.28 That's a cut from what you need, not a daily total. Someone whose body uses 2,200 calories a day would eat about 1,450–1,700.
NICE advises against restrictive diets that aren't nutritionally balanced. Low-calorie diets of 800 to 1,200 calories a day should only be used with specialist support, and for no more than 12 weeks.25
Protein: the part most people miss
When you lose weight, some of it is muscle. Too little protein makes that worse, and a smaller appetite on a GLP-1 medicine makes protein harder to get.29
- 0.8 g per kg of body weight is the usual minimum for adults.
- 1.2–1.6 g per kg has been proposed while you're losing weight.
- Don't go below 0.4–0.5 g per kg, which leads to muscle loss, or stay at 2 g per kg or more for long.29
The same advisory says to pair protein with strength exercise at least 3 times a week, plus at least 150 minutes of moderate activity like brisk walking.29 If you have kidney disease, ask your doctor before raising your protein.
What to put on the plate
NICE points people to the NHS Eatwell Guide for a balanced diet over the long term.25 You don't need every meal to match it; aim for the balance over a day or a week.30
Activity and support
Activity. The NHS advises adults to do at least 150 minutes of moderate activity a week, like brisk walking, or 75 minutes of vigorous activity, like running. It adds strengthening activities on at least 2 days a week.31 For people on a GLP-1 medicine, the US advisory above suggests strength exercise at least 3 times a week.29 NICE says people who have lost weight may need 60 to 90 minutes of activity a day to keep it off.25 Speak to your GP first if you haven't exercised for a while or have a medical condition.31
Support. NICE says that when a weight-loss medicine is prescribed, you should also be offered support with diet, activity and behaviour.9 WHO also says diet and activity programmes may be offered alongside GLP-1 medicines.32
What about pills, and other medicines that lower weight a little?
One older weight-loss pill, orlistat, is widely used in the UK. It helps a little. Some diabetes medicines also lower weight a little.
Orlistat stops about a third of the fat in your food from being absorbed; it passes out in your poo.3 It's available as Xenical on prescription, or at a lower dose as Alli or Orlos from a pharmacy.3 On the NHS it's prescribed at a BMI of 30 or more, or 28 or more with a weight-related condition such as type 2 diabetes or high blood pressure.3,9 In a 4-year trial, people on orlistat lost 5.8 kg, against 3.0 kg on a dummy pill.2 Fatty or oily poo, needing the toilet urgently and wind are common.3 The NHS says not to carry on past 3 months if you haven't lost 5% of your weight.3
Metformin is a diabetes medicine, not a licensed weight-loss one. In the Diabetes Prevention Program it led to 2.1 kg of loss on average.26 An international PCOS guideline says doctors should consider it for women with PCOS (polycystic ovary syndrome) and a BMI of 25 or more.33
SGLT2 inhibitors, such as dapagliflozin, lead to modest weight loss. Across 116 trials, people lost about 1.8 kg more than on a dummy pill.34
Naltrexone–bupropion (Mysimba) is a combination pill for weight. NICE does not recommend it for NHS use.35
Where do GLP-1 medicines fit?
They lead to more weight loss than pills or lifestyle alone. But they are a long-term treatment, and most of the weight returns if you stop.
Semaglutide (Wegovy) acts like the gut hormone GLP-1.20 Tirzepatide (Mounjaro) acts on GLP-1 and a second gut hormone, GIP.5 Guide 2 explains how they work. In every trial below, people also followed a diet and activity plan.4,5
Average weight lost in each trial. Kilograms are for someone who starts at 90 kg (14 st 2 lb).
Adults without diabetes, 68 weeks.4
Adults without diabetes, 72 weeks.5
Adults with type 2 diabetes, 68 weeks.20
The only trial that compared them directly, 72 weeks. Paid for by the maker of tirzepatide.38
Only the last trial compared the two medicines directly; the others each tested one medicine against a dummy injection, so don't compare across them.
The NHS 5% check. NICE says that if less than 5% of your starting weight has gone after 6 months, you and your prescriber should consider stopping (semaglutide) or decide whether to carry on (tirzepatide).9
Tablets. Wegovy tablets (oral semaglutide) were licensed for weight in June 2026, and Foundayo (orforglipron) in August 2026.39,40 The trial results on this page are for weekly injections.4,5
What happens when you stop. A year after stopping semaglutide, trial participants had regained about two-thirds of the weight they lost.6 In a tirzepatide trial, everyone first took the medicine for 36 weeks and lost about 21% of their weight.41 Then some were switched to dummy injections. Over the next year, their weight went up by 14% of what they weighed at the switch.41 For someone who weighed 85 kg (13 st 5 lb) by then, that is about 12 kg (85 × 0.14 = 11.9). Those who stayed on tirzepatide lost a further 5.5% over the same year.41 Guide 9 covers stopping.
Cost. On the NHS you pay the normal prescription charge: £9.90 per item in England, and nothing in Scotland, Wales or Northern Ireland.16,17,18,19 In England, people with diabetes treated with medicines can get an exemption certificate, so they don't pay.42 Privately, you pay the full price. NICE publishes Mounjaro's list price for a 4-week pen: £133 for 2.5 mg, £180 for 5 mg, £255 for 7.5 mg and 10 mg, and £330 for 12.5 mg and 15 mg, before VAT.13 Private services set their own prices on top. Guide 6 covers costs and safe ways to get them.
Who it's for. UK licences allow these medicines from a BMI of 30, or 27 with a weight-related condition.10,40 On the NHS, Wegovy and Saxenda for weight are only given in specialist weight services, for up to 2 years, and Mounjaro is being rolled out in stages through GPs in England.9,43,13 That is a point where you and a doctor can start talking about it. It does not mean you should take one. Guide 4 covers who should and shouldn't take them.
Who is weight-loss surgery for in the UK?
Surgery is for people with a higher BMI, often with a health condition that weight loss could improve. It gives the largest, longest-lasting loss, but it is a major operation.
NHS thresholds
NICE says adults should be offered a referral to a specialist weight service to see whether surgery suits them if they:9
- have a BMI of 40 or more, or
- have a BMI of 35 to 39.9 with a significant health condition that could improve with weight loss, such as type 2 diabetes, high blood pressure, sleep apnoea or fatty liver, and
- agree to long-term follow-up after surgery, such as yearly reviews for life.9
People with type 2 diabetes diagnosed in the past 10 years may get a faster assessment: offered from a BMI of 35, and considered from 30.9 For people of South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean background, NICE says to consider these thresholds 2.5 lower.9,24 Availability varies across the UK.24 Newer guidance from US and international surgeons (2022) offers surgery from a BMI of 35, or 27.5 for Asian people.8
Results
A Swedish study followed over 4,000 people. Gastric bypass led to 32% loss at its peak, and 25% after 10 years.7 Gastric banding, which puts a band around the stomach, led to less: 20% and 14%.7 People who had surgery were less likely to die during the study than similar people who didn't.7
Diabetes. In a US trial, 5 years after surgery, 29 in 100 (bypass) and 23 in 100 (sleeve) had near-normal blood sugar.46 With medicines alone, it was 5 in 100.46 In a Finnish trial, about 1 in 4 to 1 in 3 had diabetes in remission at 10 years.23
Risks
- Death around the time of the operation is rare: between 3 in 10,000 and 2 in 1,000.8
- Over 10 years, 16–19 in 100 needed another operation.23
- Acid damage to the food pipe was found in 31 in 100 after a sleeve, against 7 in 100 after a bypass.23
- Other risks include blood clots, a leak from the stomach, gallstones and excess skin.47
- NICE says the surgical service should follow you up for at least 2 years, then your GP should check your nutrition at least once a year for life.9
Cost. Surgery may be available on the NHS if you meet the criteria. You can also pay privately, which the NHS says can be expensive; we found no official private price.24
What are gastric balloons and endoscopic sleeves?
Both are done through the mouth with a camera tube (an endoscope), without cutting the skin.11,12 Neither removes any part of the stomach.11,12
Gastric balloon. A balloon is placed in the stomach using the endoscope. In a US trial, it was removed after 6 months.11 People lost 10.2% of their weight by then, against 3.3% with lifestyle alone.11 By 12 months, loss had eased to 7.6%.11 Feeling sick (87 in 100) and vomiting (76 in 100) were common, and 19 in 100 had it taken out early.11 The trial included adults with a BMI of 30 to 40.11
Endoscopic sleeve gastroplasty (ESG) reshapes the stomach from the inside.12 In a trial at nine US centres, adults with a BMI of about 30 to 40 (class 1 or 2 obesity) took part.12 They lost 13.6% at 1 year, against 0.8% with lifestyle alone.12 Serious problems happened in 2 in 100 people.12 In 2024, NICE said ESG can be used to treat obesity in adults, chosen by a specialist weight team and done only in specialist centres.22
How does the NHS build up care?
There is no single fixed order. Options can be combined, and diet and activity stay part of every plan.9,32
NHS weight services are often described in tiers. Local behavioural services are sometimes called tier 2. Specialist services, run by a team of doctors, dietitians and psychologists, include tier 3 and tier 4.48 Here is a simple picture of how the options fit:
- 1
- 2
- 3
- 4Bariatric surgeryAssessed in a specialist service. Mainly from a BMI of 40, or 35 with a related condition9
Questions people ask
Can I just diet instead?
Yes. Changing what you eat and how much you move can work on its own, with no medicine, no procedure and none of their side effects. For many people it's enough, and it's the base of every other plan. The evidence for it is strong:
- It prevents diabetes. In large trials, structured programmes led to 6–9% weight loss on average and far fewer new cases of diabetes: 58% fewer in the US trial.1,26
- Big results are possible. In a UK trial called DiRECT, people with type 2 diabetes stopped their diabetes medicines and followed a diet plan: a few months of low-calorie meal-replacement shakes, then a slow return to normal food, with support. After a year, 1 in 4 had lost 15 kg (about 2 st 5 lb) or more, and almost half no longer had diabetes. Among those who lost 15 kg or more, 86 in 100 were free of it.27
- People do keep it off. About 1 in 5 people with overweight manage to lose 10% of their weight and keep it off for at least a year. A US registry of people who succeeded has members who lost an average of 33 kg (about 5 st 3 lb) and kept it off for more than 5 years.49
What the people who keep it off have in common: about an hour of activity a day, a lower-calorie diet, eating breakfast, weighing themselves regularly, and eating the same way on weekdays and weekends.49
Not everyone gets these best results: trial averages are smaller, and some weight often creeps back over the years.1 If diet and activity alone don't get you far enough, medicines are added on top, not used instead.9
Is surgery safer than lifelong injections?
They're usually for different people. On the NHS, surgery is mainly for a BMI of 40 or more, or 35 or more with a related condition.9 GLP-1 medicines are licensed from a BMI of 30, or 27 with a weight-related condition.10 So at a BMI in the high 20s, surgery usually isn't on the table. Where both are options, they carry different risks. Surgery has a small risk of death at the time, and some people need a second operation.8,23 GLP-1 medicines have ongoing side effects, and most of the weight returns if you stop.21,6 Surgery may be available on the NHS if you meet the criteria; medicines carry a prescription charge in England, or the full price if you go private, for as long as you take them.24,16,13
Do herbal or "natural" slimming products work?
NICE's list of weight-loss medicines doesn't include any herbal product.9 In the US, many slimming products sold as supplements or "all-natural" have been found to contain hidden drugs.36 The NHS warns that some websites sell fake weight-loss medicines.3
Can I take metformin to lose weight?
Metformin isn't a weight-loss medicine. In a large trial, it led to about 2 kg of loss.26 Doctors use it for type 2 diabetes, and for some women with PCOS.33
If I take a GLP-1, do I still need to change what I eat?
Yes. NICE says all weight-loss medicines should be used alongside a reduced-calorie diet and more physical activity.9 WHO also says diet and activity support should go alongside them.32
Before you move on
- Lifestyle changes are the base of every option, including medicines and surgery.
- Orlistat is the main older weight-loss pill in the UK, and it helps a little.
- GLP-1 medicines lead to more loss, but weight returns on stopping. NHS criteria are stricter than the licence.
- Surgery gives the most lasting loss, but it's a major operation with lifelong follow-up.
- There's no fixed order. A doctor matches the option to you.
Sources
- Pi-Sunyer X. The Look AHEAD trial: a review and discussion of its outcomes. Curr Nutr Rep, 2014. DOI · Full text
- Torgerson JS et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care, 2004. DOI
- NHS. Orlistat: medicine information (common brands Alli, Orlos, Xenical). Checked 12 October 2026. nhs.uk
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM, 2021. DOI
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). NEJM, 2022. DOI
- Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab, 2022. DOI
- Sjöström L et al. Effects of bariatric surgery on mortality in Swedish obese subjects (SOS). NEJM, 2007. DOI
- Eisenberg D et al. 2022 ASMBS and IFSO indications for metabolic and bariatric surgery. Obes Surg, 2023. DOI · Full text
- NICE. Overweight and obesity management (NG246), section "Medicines and surgery": table 1 (medicines, who they're for, setting, when to stop) and recommendations 1.17–1.18 (bariatric surgery). Last updated 8 January 2026. nice.org.uk
- Novo Nordisk. Wegovy 2.4 mg FlexTouch, summary of product characteristics (UK label), section 4.1. Date of revision 09/2026. emc
- Courcoulas A et al. Intragastric balloon as an adjunct to lifestyle intervention: a randomized controlled trial. Int J Obes, 2017. DOI
- Abu Dayyeh BK et al. Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT). Lancet, 2022. DOI
- NICE. Tirzepatide for managing overweight and obesity (TA1026), 23 December 2024. Section 2.3 gives list prices for a 4-week supply, excluding VAT; section 4 and "What this means in practice" describe the phased rollout in England. nice.org.uk
- Look AHEAD Research Group. Eight-year weight losses with an intensive lifestyle intervention: the Look AHEAD study. Obesity, 2014;22(1):5–13 (26.9% of the lifestyle group had lost 10% or more at year 8). DOI
- NHS Health Check. Healthier You: NHS Diabetes Prevention Programme ("available to every adult in England" identified at high risk of type 2 diabetes). Checked 12 October 2026. healthcheck.nhs.uk
- NHS Business Services Authority. NHS prescription prepayment certificate (PPC); prescription charge in England £9.90 per item. Checked 12 October 2026. nhsbsa.nhs.uk
- Citizens Advice Scotland. Help with health costs ("Prescriptions in Scotland are free"). Checked 12 October 2026. citizensadvice.org.uk
- Welsh Government. Free prescriptions. gov.wales
- nidirect. Help with health costs ("All prescriptions dispensed in Northern Ireland are free of charge for everyone"). nidirect.gov.uk
- Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet, 2021. DOI
- Novo Nordisk. Wegovy (semaglutide) prescribing information, US label (FDA), revised June 2026: warnings on pancreatitis, gallbladder disease, acute kidney injury and thyroid C-cell tumours. Not the UK label. DailyMed
- NICE. Endoscopic sleeve gastroplasty for obesity (interventional procedures guidance IPG783, now HealthTech guidance HTG711), 22 February 2024. nice.org.uk
- Salminen P et al. Sleeve gastrectomy vs Roux-en-Y gastric bypass at 10 years (SLEEVEPASS). JAMA Surg, 2022. DOI
- NHS. Why weight loss surgery is done. Page last reviewed 5 February 2024. nhs.uk
- NICE. Overweight and obesity management (NG246), section "Physical activity and diet", recommendations 1.15–1.16. nice.org.uk
- Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. NEJM, 2002. DOI · Full text
- Lean MEJ, Leslie WS, Barnes AC et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet, 2018;391(10120):541–551. 306 people in Scotland and England. DOI
- Jensen MD, Ryan DH, Apovian CM et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults. Circulation, 2014;129(25 Suppl 2):S102–38 ("500- to 750-kcal/d deficit"). DOI
- Mozaffarian D, Agarwal M, Aggarwal M et al. Nutritional priorities to support GLP-1 therapy for obesity: a joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society. American Journal of Clinical Nutrition, 2025;122(1):344–367. DOI · PMC12612741
- NHS. The Eatwell Guide. Checked 12 October 2026. nhs.uk
- NHS. Physical activity guidelines for adults aged 19 to 64. Checked 12 October 2026. nhs.uk
- World Health Organization. WHO issues global guideline on the use of GLP-1 medicines in treating obesity. News release, 1 December 2025. WHO
- Teede HJ et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril, 2023. Declared interests: 1 of 13 named authors declares speaker fees from Novo Nordisk (paper's own declaration). DOI
- Cheong AJY et al. SGLT inhibitors on weight and body mass: a meta-analysis of 116 randomized-controlled trials. Obesity, 2022. DOI
- NICE. Naltrexone–bupropion for managing overweight and obesity (TA494), 12 December 2017: "not recommended". nice.org.uk
- US Food and Drug Administration. Weight loss product notifications (medication health fraud). Updated 4 September 2026. FDA
- MHRA. GLP-1 medicines for weight loss and diabetes: what you need to know. Updated 5 February 2026. gov.uk
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). NEJM, 2025. DOI
- MHRA. First GLP-1 tablet for weight loss approved in the UK (Wegovy tablets). 11 June 2026. gov.uk
- MHRA. UK first in Europe to authorise orforglipron for weight management and type 2 diabetes. 10 August 2026. gov.uk
- Aronne LJ et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA, 2024. DOI
- NHS Business Services Authority. Medical exemption certificates (includes "diabetes mellitus, except where treatment is by diet alone"). nhsbsa.nhs.uk
- NICE. Semaglutide for managing overweight and obesity (TA875), 8 March 2023 (specialist weight management services only, for up to 2 years). nice.org.uk
- MHRA. MHRA updates guidance for GLP-1 prescribers and patients (risk of severe acute pancreatitis). 29 January 2026. gov.uk
- MHRA. Yellow Card scheme: report a suspected side effect. yellowcard.mhra.gov.uk
- Schauer PR et al. Bariatric surgery versus intensive medical therapy for diabetes: 5-year outcomes (STAMPEDE). NEJM, 2017. DOI
- NHS. Complications of weight loss surgery. Page last reviewed 5 February 2024. nhs.uk
- NICE. Overweight and obesity management (NG246), "Terms used in this guideline" (behavioural services, "sometimes called tier 2"; specialist services, "including but not limited to tier 3 and tier 4"). nice.org.uk
- Wing RR, Phelan S. Long-term weight loss maintenance. American Journal of Clinical Nutrition, 2005;82(1 Suppl):222S–225S. Registry members volunteer, so they are not a random sample. DOI
Last checked 12 Oct 2026 · Next review due Jan 2027 · Report an error
How this guide was made. Written by the GLP Guidebook team from the sources above: NICE and NHS guidance, MHRA notices, published trials, and official list prices published by NICE. We don't list or compare private providers' prices. It's general information, not medical advice. Talk to your GP or another qualified health professional before starting, stopping or changing any treatment. In an emergency, call 999. For urgent help that isn't an emergency, use NHS 111 (in Northern Ireland, call your GP surgery for the out-of-hours service). How we write